QTRX

Quanterix Corp

2.81

Nov 02 • 3:59 PM ET 0.00 (0.00%)

Healthcare Medical Devices USA Micro NASD

Peers: ALMR QSI LAB NAUT SEER TXG CTKB MASS PACB BIO

| Held by: VTI IWM VXF IWN VTWO IBB FESM DFMC VHT IWC

Index	RUT
Market Cap	132.89M
Enterprise Value	72.75M
Income	-123.11M
Sales	153.41M
Book/sh	5.03
Cash/sh	1.98
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	450
IPO	Dec 07, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	0.87
P/B	0.56
P/C	1.42
P/FCF	-
EV/EBITDA	-
EV/Sales	0.47
Quick Ratio	2.45
Current Ratio	3.40
Debt/Eq	0.14
LT Debt/Eq	0.11
Option/Short	Yes / Yes

EPS (ttm)	-2.63
EPS next Y	-1.24
EPS next Q	-0.42
EPS this Y	10.76%
EPS next Y	44.80%
EPS next 5Y	25.85%
EPS past 3/5Y	2.27% -18.72%
Sales past 3/5Y	9.59% 9.97%
EPS Y/Y TTM	-44.65%
Sales Y/Y TTM	21.96%
EPS Q/Q	-34.44%
Sales Q/Q	34.44%
Earnings	Nov 09 BMO
EPS/Sales Surpr.	-153.47% -12.20%

Insider Own	11.73%
Insider Trans	1.89%
Inst Own	62.32%
Inst Trans	-16.71%
ROA	-35.42%
ROE	-46.49%
ROIC	-46.85%
Gross Margin	42.69%
Oper. Margin	-63.91%
Profit Margin	-80.25%
SMA20	-6.71%
SMA50	-5.84%
SMA200	-26.88%
Trades

Shs Outstand	47.13M
Shs Float	41.75M
Short Float	11.21%
Short Ratio	6.27
Short Interest	4.68M
52W High	8.77 -67.96%
52W Low	2.15 30.70%
Volatility	7.15% 7.26%
ATR (14)	0.21
RSI (14)	42.66
Beta	1.02
Rel Volume	0.00
Avg Volume	746.57K
Volume	0

Perf Week	-0.71%
Perf Month	-22.80%
Perf Quarter	-24.26%
Perf Half Y	-16.62%
Perf YTD	-55.82%
Perf Year	-47.38%
Perf 3Y	-87.39%
Perf 5Y	-94.64%
Perf 10Y	-
Recom	3.00
Target Price	3.17
Prev Close	2.81
Price	2.81
Change %	0.00%

Consensus

Hold

Avg. Price Target

$3.17

Implied Upside

+12.8%

Analysts6incl. previous ratings

Rating Distribution3 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 11, 2025	Downgrade	CCanaccord Genuity	Buy → Hold	$5	+77.9%
Feb 01, 2024	Initiated	BScotiabank	Sector Outperform	$30	+967.6%
Sep 25, 2023	Upgrade	CCanaccord Genuity	Hold → Buy	$25 → $32	+1,038.8%
Aug 08, 2023	Upgrade	SSVB Securities	Market Perform → Outperform	$30	+967.6%
May 23, 2023	Upgrade	GGoldman	Neutral → Buy	$13 → $27	+860.9%
Aug 15, 2022	Downgrade	CCanaccord Genuity	Buy → Hold	$40 → $12	+327.0%
Aug 09, 2022	Downgrade	SSVB Leerink	Outperform → Mkt Perform	$35 → $15	+433.8%
Aug 09, 2022	Downgrade	CCowen	Outperform → Market Perform	$38 → $18	+540.6%
Mar 02, 2022	Upgrade	GGoldman	Sell → Neutral	$40	+1,323.5%
Oct 15, 2021	Resumed	CCowen	Outperform
Jun 04, 2021	Initiated	GGoldman	Sell	$53	+1,786.1%

Oct-28-26 04:30PM	Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026 (Business Wire) +7.96%
Oct-07-26 08:00AM	Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals (Business Wire)
Sep-25-26 08:00AM	Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026 (Business Wire)
Sep-16-26 09:00PM	Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.99% +7.22%
Sep-14-26 08:00AM	Quanterix Names Dr. Yuri Fesko Chief Medical Officer (Business Wire)
05:01PM	Loading…
Aug-10-26 05:01PM	Quanterix Corp (QTRX) (Q2 2026) Earnings Call Highlights: Revenue Miss and Guidance Cut Amid ... (GuruFocus.com) -39.95% +8.47%
11:04AM	Quanterix Cuts 2026 Revenue Outlook as Commercial Challenges Delay Cash-Flow Break-Even (InvestorsHub)
08:01AM	Quanterix Names Jim Gute Chief Commercial Officer (Business Wire)
08:00AM	Quanterix Releases Financial Results for the Second Quarter of 2026 (Business Wire)
Aug-07-26 09:22AM	Earnings To Watch: Quanterix Corp (QTRX) Q2 2026 -- GF Value Sees 253% Upside (GuruFocus.com) +5.22%
Aug-06-26 08:00AM	Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12 (Business Wire)
Aug-04-26 08:00AM	Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026 (Business Wire)
Jul-16-26 04:05PM	Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.60%
Jul-14-26 04:29PM	Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages (Business Wire) +5.15%
Jun-23-26 09:55PM	TRIB, QTRX, RCON: Why These Stocks Are Surging After-Hours Today (Stocktwits) -7.74% +17.39%
04:01PM	Loading…
Jun-16-26 04:01PM	Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.88%
Jun-09-26 08:03AM	Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer (Business Wire)
Jun-04-26 08:02AM	Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics (Business Wire) +7.65%
Jun-03-26 08:01AM	Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
May-26-26 04:01PM	Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-12-26 04:01PM	Quanterix Announces Planned Transition of Chief Financial Officer (Business Wire)
May-06-26 04:01PM	Quanterix Releases Financial Results for the First Quarter of 2026 (Business Wire) -16.41%
Apr-24-26 08:33AM	Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026 (Business Wire)
Apr-17-26 08:33AM	AidaBREAST Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology (Business Wire)
Apr-15-26 08:33AM	Quanterix Debuts Content Innovation Engine at AACR 2026 (Business Wire) +6.19%
Mar-27-26 04:00PM	Quanterix Corporation Announces Date of 2026 Annual Meeting (Business Wire) -8.21%
Mar-03-26 12:01AM	Quanterix Corp (QTRX) Q4 2025 Earnings Call Highlights: Revenue Surge Amidst Strategic Shifts (GuruFocus.com) -7.27%
Mar-02-26 05:32PM	Quanterix Q4 Earnings Call Highlights (MarketBeat)
05:10PM	Quanterix Corporation (QTRX) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:01PM	Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025 (Business Wire)
08:33AM	Loading…
08:33AM	Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide (Business Wire)
Feb-27-26 07:21AM	Quanterix Corp (QTRX) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-26-26 06:00PM	Curaleaf Holdings, Inc. (CURLF) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +6.84%
08:33AM	Quanterix to Participate in Upcoming Investor Conferences (Business Wire)
Feb-20-26 08:33AM	Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 (Business Wire)
Feb-04-26 12:57PM	Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test (Zacks)
Feb-03-26 08:33AM	Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimers Disease Detection (Business Wire)
Jan-21-26 08:33AM	Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling (Business Wire)
Jan-16-26 04:01PM	Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.92% -5.14%
Jan-08-26 04:30PM	Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 (Business Wire) +23.81%
Dec-22-25 07:30AM	Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence (Business Wire)
Nov-20-25 04:15PM	Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth (Business Wire) +12.69%
Nov-17-25 05:30PM	Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring (Business Wire)
Nov-11-25 12:02AM	Quanterix Corp (QTRX) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com)
Nov-10-25 05:10PM	Quanterix Corporation (QTRX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Quanterix Releases Financial Results for the Third Quarter of 2025 (Business Wire)
Nov-07-25 07:35AM	Sanuwave Health Inc. (SNWV) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:22AM	Earnings To Watch: Quanterix Corp (QTRX) Reports Q3 2025 Result (GuruFocus.com)
Nov-03-25 07:00AM	Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025 (Business Wire)
Oct-02-25 12:00PM	All You Need to Know About Quanterix (QTRX) Rating Upgrade to Buy (Zacks)
Aug-21-25 04:30PM	Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit (Business Wire)
Aug-12-25 09:35AM	Down 24.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Quanterix (QTRX) (Zacks)
Aug-11-25 07:00AM	Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
Aug-07-25 06:35PM	Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -13.79%
04:06PM	Quanterix Releases Financial Results for the Second Quarter of 2025 (Business Wire)
Aug-04-25 04:02PM	Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
09:30AM	Quanterix Announces Cooperation Agreement with Kent Lake Capital (Business Wire)
Jul-28-25 07:00AM	Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC (Business Wire) +10.94%
Jul-24-25 08:45AM	Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Jul-11-25 05:00PM	Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-08-25 09:07AM	Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum (Business Wire)
Jun-23-25 07:30AM	Quanterix Expands Reach with IVD and Large Reference Labs (Business Wire)
Jun-11-25 08:00AM	Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders (PR Newswire)
Jun-06-25 09:41AM	Quanterix to Present at Goldman Sachs Global Healthcare Conference (Business Wire)
May-23-25 02:21PM	Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal (PR Newswire)
09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
May-13-25 03:09AM	Quanterix Corp (QTRX) Q1 2025 Earnings Call Highlights: Record Consumables Revenue Amidst ... (GuruFocus.com) -19.02%
May-12-25 05:10PM	Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.52%
04:01PM	Quanterix Releases Financial Results for the First Quarter of 2025 (Business Wire)
May-09-25 09:42AM	Earnings To Watch: Quanterix Corp (QTRX) Reports Q1 2025 Result (GuruFocus.com)
May-07-25 07:40PM	Phibro Animal Health (PAHC) Q3 Earnings Beat Estimates (Zacks)
May-05-25 07:00AM	Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025 (Business Wire)
Apr-30-25 08:00AM	Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders (Business Wire)
Apr-29-25 07:00AM	Quanterix and Akoya Biosciences Announce Amended Merger Agreement (Business Wire)
Apr-17-25 08:30AM	Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders (Business Wire)
Apr-14-25 08:00AM	Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences (Business Wire) +7.69%
Apr-07-25 08:15AM	Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya (Business Wire) -12.96%
Apr-02-25 09:41AM	Quanterix: Still Many, Many Questions (Seeking Alpha)
Apr-01-25 01:00AM	Quanterix Showcases Innovation Powered by Simoa at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit (Business Wire)
Mar-24-25 11:03AM	Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences (Business Wire)
Mar-19-25 04:10PM	SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN (PR Newswire)
Mar-18-25 09:18AM	Q4 2024 Quanterix Corp Earnings Call (Thomson Reuters StreetEvents)
03:01AM	Quanterix Corp (QTRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com)
Mar-17-25 04:01PM	Quanterix Releases Financial Results for the Fourth Quarter of 2024 (Business Wire)
04:00PM	Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Todays Earnings Call (Business Wire)
04:00PM	Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results (GlobeNewswire)
Mar-13-25 01:00PM	Quanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025 (Business Wire)
Mar-11-25 08:00AM	Kent Lake Issues Investor Presentation Detailing Opposition to Quanterixs Proposed Merger with Akoya Biosciences (Business Wire)
Mar-03-25 08:00AM	Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board (Business Wire) -6.59%
06:00AM	Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition (Business Wire)
Feb-18-25 03:40PM	Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Companys Proposed Merger with Akoya Biosciences (Business Wire)
Jan-14-25 07:00AM	Quanterix Provides Update on Financial Performance (Business Wire) -5.93%
Jan-10-25 07:00AM	Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers (Business Wire) -19.69%
Jan-06-25 09:30AM	David R. Walt Receives National Medal of Technology and Innovation (Business Wire)
Jan-02-25 04:26PM	Quanterix to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) +12.27%
Dec-27-24 04:33AM	Down More Than 60%: Analysts Expect These 2 Beaten-Down Stocks to Rebound in 2025 (TipRanks)
Dec-17-24 06:59AM	Quanterix Expands Capabilities with Strategic Acquisition of EMISSION (Business Wire)
Nov-22-24 05:00PM	Quanterix Announces Receipt of Expected Notice from Nasdaq (Business Wire) +5.70%
07:54AM	Wolf Haldenstein Adler Freeman and Herz LLP announces that it is investigating Quanterix Corporation for potential violations of securities laws (GlobeNewswire)
Nov-21-24 07:00AM	Wolf Haldenstein Adler Freeman and Herz LLP announces that it is investigating Quanterix Corporation for potential violations of securities laws (PR Newswire) +6.35%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DONNELLY WILLIAM P	Director	Aug 13 '26	Buy	2.93	72,245	211,678	99,400	Aug 14 04:01 PM
DONNELLY WILLIAM P	Director	Aug 12 '26	Buy	2.75	27,155	74,676	27,155	Aug 14 04:01 PM
Meadows Benjamin	Chief Commercial Officer	May 12 '26	Buy	2.77	3,500	9,695	3,500	Jun 12 05:32 PM

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Executive ChairMr. William P. Donnelly

Co-Founder & Chairman of Scientific Advisory BoardDr. David R. Walt Ph.D.

PresidentMr. Everett V. Cunningham

CFO & TreasurerMr. Jason Faessler

Chief Operating OfficerMr. Anthony Catalano

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QTRX

Quanterix Corp

Upgrade your Finviz experience